- AnovaOS™ has been used to design, manage and deliver an early access program for NEO100;
- AnovaOS™ will be used to support patient identification and enrolment to clinical trials through just-in-time approach.
Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, and the industry’s first collaborative ‘learning system’, today announced a partnership with the NeOnc Technologies, Inc. (NeOnc) to accelerate the development of NEO100 for patients with IDH1 mutated gliomas.
NeOnc is a developer of a novel molecular technology that provides enhanced targeted delivery of therapeutics for the treatment of CNS-based diseases. As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.
The just-in-time activation and enrolment model is delivering treatment to eligible patients in five days.
“Our partnership with NeOnc is another example of Anova’s commitment to improving access to promising new treatments for patients in need, in diseases where patients are often left with limited treatment options,’ said Martin Walsh, President at Anova. ‘AnovaOS™ is designed to allow rare and complex disease populations to access the right treatment wherever they choose to receive care.’
“We look forward to working with Anova, and helping to accelerate development efforts for NEO100. Results of studies of NEO100 for patients with IDH1 mutations are promising, and our partnership with Anova will help accelerate the delivery of further research programs in readiness for a regulatory submission.,” said Dr Thomas Chen, MD, PhD, Chief Executive and Chief Scientific Officer of NeOnc.
